The run-in phase of the prospective WSG-ADAPT HR+/HER2– trial demonstrates the feasibility of a study design combining static and dynamic biomarker assessments for individualized therapy in early breast cancer

The run-in phase of the prospective WSG-ADAPT HR+/HER2– trial demonstrates the feasibility of a study design combining static and dynamic biomarker assessments for individualized therapy in early breast cancer

Background: Endocrine sensitivity, as determined by response of the proliferation marker Ki-67 to short-term preoperative endocrine therapy (ET), is currently not included in adjuvant treatment decisions in hormone receptor (HR)+/human epidermal growth factor receptor 2 (HER2)− breast cancer (BC). M...

Full description

Bibliographic Details
Main Authors: Ulrike Nitz, Oleg Gluz, Hans H. Kreipe, Matthias Christgen, Sherko Kuemmel, Frederick L. Baehner, Steven Shak, Bahriye Aktas, Michael Braun, Kerstin Lüdtke-Heckenkamp, Helmut Forstbauer, Eva-Maria Grischke, Benno Nuding, Maren Darsow, Claudia Schumacher, Katja Krauss, Wolfram Malter, Marc Thill, Mathias Warm, Rachel Wuerstlein, Ronald E. Kates, Nadia Harbeck
Format: Article
Language:English
Published: SAGE Publishing 2020-11-01
Series:Therapeutic Advances in Medical Oncology
Online Access:https://doi.org/10.1177/1758835920973130

Internet

https://doi.org/10.1177/1758835920973130

Similar Items